Piscataway, NJ, April 26, 2024– Camber Pharmaceuticals is thrilled to announce the addition of Aripiprazole Oral Solution to its product line, complementing the existing product family that included Aripiprazole Tablets. Camber initially launched Aripiprazole Tablets in 2015, as one of the first generic alternatives to Abilify®, significantly expanding patient access to this life-changing medication.
Aripiprazole Oral Solution is indicated for the treatment of:
- Schizophrenia
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
- Irritability Associated with Autistic Disorder
- Treatment of Tourette’s Disorder
Aripiprazole Oral Solution 1 mg/mL is available in 150 mL child-resistant bottles along with a calibrated oral dosing cup.
To learn more about Aripiprazole Oral Solution, please visit https://www.camberpharma.com/aripiprazole-oral-sol
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
